[ad_1]
In a presentation to the Presidential Advisory Council on Antibiotic Bacteria – or PACCARB – Tom Lowery, PhD, T2 Biosystems' scientific lead discussed new technologies that allow physicians to quickly select effective antibiotics, improve patient care and combat antibiotic resistance.
PACCARB was created in 2015 after the president Barack Obama directed the federal agencies to take action against the health threat posed by antibiotic resistance and to implement the recommendations made in a report by the President's Council of Science and Technology Advisors.
Lowery's presentation focused on clinical experiences demonstrating that T2 Biosystems' proprietary T2 magnetic resonance detection method provides early, targeted and effective antibiotic therapy for patients with blood infections. At the meeting, Lowery explained the importance of technology, saying that every hour of late and effective use of antibiotics can extend the length of hospital stay by up to 3 hours.
"At the present time, patients are treated for infections empirically without knowing if they are actually infected, which often exposes them to incorrect or unnecessary antibiotic treatment," Lowry said in a statement. Press. "This greatly reduces their chances of survival and increases the problem of antimicrobial resistance. With the advent of independent cultural tests like ours, the era of blind guessing about patient therapy can come to an end.
During the presentation, Lowery also discussed the company's portfolio of diagnostic tools for rapid identification of pathogens and resistance genes responsible for sepsis. According to the press release, the portfolio includes the T2Bacteria and T2Candida panels, which are the only FDA-approved badyzes available to US health care providers to date for the detection of sepsis pathogens without the risk of sepsis. it is necessary to practice a blood culture.
"We need to change the treatment of patients for blood infections and sepsis, otherwise current generations will continue to die unnecessarily and future generations will have a reduced arsenal of antibiotics," Lowery said in a press release. "I am honored to have the opportunity to present our data and describe [how] new opportunity for T2 Biosystems technology to improve patient care [Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria]. "
Bacteriophages as alternative antibiotic options, the challenges of pharmaceutical development and the prioritization of vaccines to reduce the use of antibiotics in animals were also discussed. – by Caitlyn Stulpin
Reference:
Lowery T. Earlier effective antibiotic therapy by independent diagnoses of the culture. Presented at: PACCARB; January 30, 2019; Washington.
Disclosure: Lowery works for T2 Biosystems.
[ad_2]
Source link
